Menu
← Oncology Approval Tracker
FDA DECISION ·
Verzenio + endocrine therapy
abemaciclib + tamoxifen or an aromatase inhibitor · Eli Lilly
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adjuvant treatment for adults with HR-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence. This action removed the prior Ki-67 testing requirement.
LAMPGEN ANALYSIS
Why it matters
The approval broadened access to qualifying high-risk patients without a Ki-67 result.
What research teams should watch
Apply nodal and clinicopathologic high-risk criteria rather than the older Ki-67 threshold.
PRIMARY RECORDS